ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Dana-Farber Cancer Institute at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Dana-Farber Cancer Institute takes part in 48 sessions at ESMO 2026 in Madrid. Its program spans breast cancer treatment, immunotherapy and biomarkers. Topics include personalized cancer vaccines and using blood-based DNA profiling to track treatment resistance in prostate and pancreatic cancers.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Cancer treatment and research institute in Boston, Massachusetts, and a teaching affiliate of Harvard Medical School.
Satellite
Fri Oct 23
10:15–10:40
HER2-Positive Breast Cancer: ADC Strategies for First-Line Metastatic and Early Disease
Medscape Global Oncology - Redrawing the Breast Cancer Roadmap: Advancing Novel Therapies Into First-Line and Early Disease Settings
Breast cancer
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Higher GCN2 expression is associated with favorable clinical and genomic features in advanced prostate cancer
ePoster session 12
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Tumor mutational profiles and clinical predictors in late recurrence (>5 years) of skin-limited melanoma
ePoster session 11
Melanoma & skin cancersBiomarkers & precision oncology
Talk
Fri Oct 23
14:10–14:30
Personalising vaccines using peptides, DNA, mRNA and more
Melanoma: From standard fit to bespoke care
Melanoma & skin cancers
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Cell-free chromatin epigenomic profiling enables non-invasive subtyping of pancreatic cancer
Friday Poster Display session 2
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Characterizing the long tail of somatic mutations in clear-cell renal cell carcinoma (ccRCC)
Friday Poster Display session 5
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Clinical and transcriptomic correlates of primary resistance to nivolumab plus ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC)
Friday Poster Display session 5
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Comprehensive plasma epigenomic profiling derived lineage states in mCRPC associate with 177Lu-PSMA-617 response and resistance
Friday Poster Display session 2
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Decoding tumor gene expression from circulating chromatin at single-gene resolution
Friday Poster Display session 3
Gastrointestinal cancersGenitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Functional epigenomic liquid biopsy to guide treatment at EV/P resistance in metastatic urothelial carcinoma (mUC): Emerging role of ERBB3
Friday Poster Display session 5
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Talk
Fri Oct 23
15:35–15:55
Perspectives from the medical oncologist
What oncologists should know about mRNA vaccines
Chair
Fri Oct 23
16:15–17:00
The best is yet to come: Immune modulating approaches in neuro- oncology
Sarcoma, CNS, head & neck and rare cancers
Satellite
Fri Oct 23
18:20–18:30
Resectable NSCLC: Personalized treatment selection and patient support to optimize outcomes
AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care
Lung & thoracic cancersBiomarkers & precision oncology
Satellite
Fri Oct 23
19:15–19:30
From breakthrough to backbone: The evolving role of immunotherapy across stages of
AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care
Lung & thoracic cancersBiomarkers & precision oncology
Chair
Sat Oct 24
08:30–10:00
Rapid oral 1: NSCLC, metastatic
with MD Anderson Cancer Center, Leiden University Medical Center
Lung & thoracic cancers
Abstract
Sat Oct 24
09:10–09:22
Invited Discussant LBA74 and 2636RO
Rapid oral 1: NSCLC, metastatic
Lung & thoracic cancers
Poster
Sat Oct 24
12:00–12:45
Clinical and molecular characteristics of leptomeningeal disease in metastatic breast cancer patients: A prospective observational registry study
Saturday Poster Display session 3
Breast cancerSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Inpatient outcomes of myocarditis in cancer patients in the immunotherapy era: A national cohort study, 2020–2023
Saturday Poster Display session 5
Nursing & supportive care
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Satellite
Sat Oct 24
13:20–13:40
Recent Updates in Resectable LA HNSCC
MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC
Sarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
13:40–14:10
MDT Case Discussion
MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC · with The Royal Marsden, Lausanne University Hospital (CHUV), Hospital Universitario Fundación Jiménez Díaz
Sarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
18:40–18:55
Defining High Risk: Leveraging RWE to Inform Treatment Decisions
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision
Breast cancer
Satellite
Sat Oct 24
18:55–19:05
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Evangelische Kliniken Essen-Mitte, Latin American Cooperative Oncology Group
Breast cancer
Satellite
Sat Oct 24
19:20–19:30
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Latin American Cooperative Oncology Group, Evangelische Kliniken Essen-Mitte
Breast cancer
Satellite
Sat Oct 24
19:40–19:50
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Evangelische Kliniken Essen-Mitte, Latin American Cooperative Oncology Group
Breast cancer
Abstract
Sun Oct 25
08:30–08:40
Talk
Sun Oct 25
08:45–09:00
Personalized cancer vaccines
All about cancer vaccines
Chair
Sun Oct 25
10:15–11:45
Talk
Sun Oct 25
10:15–10:35
Optimising systemic therapy and sequence for stage I HER2-positive early breast cancer
Optimising treatment for HER2+ early breast cancer
Breast cancer
Abstract
Sun Oct 25
10:35–10:45
Invited Discussant 690O and 691O
Proffered paper: CNS tumours
Sarcoma, CNS, head & neck and rare cancers
Abstract
Sun Oct 25
10:35–10:47
Invited Discussant LBA29 and LBA30
Proffered paper: Gastrointestinal tumours, lower digestive
Gastrointestinal cancers
Talk
Sun Oct 25
11:15–11:30
The modern oncologist: Leading teams in an era of complexity
ESMO-ASCO: The evolving definition of the modern oncologist
Satellite
Sun Oct 25
13:35–13:55
Deep Dive: The Pivotal Evidence Base in nmCRPC
Medscape Global Oncology - Navigating the New Era of mHSPC and nmCRPC: Data-Driven Strategies for Therapy Selection
Genitourinary cancers
Satellite
Sun Oct 25
13:45–14:05
Exploring window-of-opportunity trials and ctDNA-based approaches to further optimise the early stage setting with oral SERDs
F. Hoffmann - La Roche LTD - Next-era strategies in HR+ HER2– early breast cancer: Optimising endocrine therapy
Breast cancer
Satellite
Sun Oct 25
13:55–14:25
Expert Quickfire on Clinical Decision-Making: From Data to Practice in mHSPC and nmCRPC
Medscape Global Oncology - Navigating the New Era of mHSPC and nmCRPC: Data-Driven Strategies for Therapy Selection · with University Medical Center Freiburg, University of California San Diego
Genitourinary cancers
Abstract
Sun Oct 25
14:45–14:50
Talk
Sun Oct 25
15:15–16:00
From medical student to oncologist: How to plan the career path
YO Medical Students session: ESMO for medical students and young physicians · with Fudan University Shanghai Cancer Center, Hacettepe University, Peter MacCallum Cancer Centre
Abstract
Sun Oct 25
15:39–15:44
Satellite
Sun Oct 25
18:38–19:33
Clinical Snapshots: Applying an Individualised Approach in MBC
Pfizer Oncology - Metastatic Breast Cancer: Individualised Decision- Making in Focus · with Hospital Arnau de Vilanova, Institut de Cancérologie de l'Ouest, University Medical Center Hamburg-Eppendorf
Breast cancer
Satellite
Sun Oct 25
18:40–19:10
ADC Biomarkers and their Current Role in Patients with NSCLC with Actionable Genomic
Daiichi Sankyo - Patient Identification in NSCLC: 10 From Actionable Genomic Alterations to Emerging ADC Opportunities
Lung & thoracic cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
19:33–19:48
Redefining the Future: Personalised Maintenance Strategies in HER2+ MBC
Pfizer Oncology - Metastatic Breast Cancer: Individualised Decision- Making in Focus
Breast cancer
Satellite
Sun Oct 25
19:48–19:58
Ask the Expert: Panel Discussion and Audience Q&A
Pfizer Oncology - Metastatic Breast Cancer: Individualised Decision- Making in Focus · with Hospital Arnau de Vilanova, Institut de Cancérologie de l'Ouest, University Medical Center Hamburg-Eppendorf
Breast cancer
Talk
Mon Oct 26
10:15–10:35
Presentation by Expert
Challenges in the management of neuro-endocrine and small cell prostate cancer
Genitourinary cancers
Chair
Mon Oct 26
10:30–11:15
YO Brunch 3
with Sestre milosrdnice University Hospital Centre
Poster
Mon Oct 26
12:00–12:45
Biomarkers associated with response to the CAR-T cell therapy LB2102 in subjects with SCLC or LCNEC
Monday Poster Display session 4
Lung & thoracic cancersBiomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Abstract
Mon Oct 26
17:30–17:42
Invited Discussant LBA11
Presidential Symposium III
Gynaecological cancersSarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Dana-Farber Cancer Institute

Tell us what you sell and we’ll find the people at Dana-Farber Cancer Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction